Pondé Noam, Dal Lago Lissandra, Azim Hatem A
a BrEAST Data Centre, Department of Medicine, Institut Jules Bordet , Université Libre de Bruxelles , Brussels , Belgium.
b Medicine Department, Institut Jules Bordet , Université Libre de Bruxelles , Brussels , Belgium.
Expert Rev Anticancer Ther. 2016 Jun;16(6):661-71. doi: 10.1586/14737140.2016.1170595. Epub 2016 Apr 8.
Elderly women with early breast cancer (BC) form a heterogeneous and large subgroup (41.8% of women with BC are over 65). Decision making in this subgroup is made more difficult by lack of familiarity with their physical, cognitive and social issues. Adequate management depends on biological factors and accurate clinical evaluation through comprehensive geriatric assessment (CGA). CGA can help to better select and determine potential risks factors for patients who are candidates for adjuvant chemotherapy. It is still recently introduced in geriatric oncology and there is a lack of awareness of its importance. Available data on adjuvant chemotherapy for BC is limited but suggests it can be of benefit for well selected patients, though the risk of short and long-term toxicity is significant. Here we provide a discussion of the key practical issues in decision making in the setting of adjuvant chemotherapy for elderly BC patients.
患有早期乳腺癌(BC)的老年女性构成了一个异质性的大群体(41.8%的乳腺癌女性患者年龄超过65岁)。由于对她们的身体、认知和社会问题缺乏了解,该亚组的决策变得更加困难。充分的管理取决于生物学因素以及通过综合老年评估(CGA)进行准确的临床评估。CGA有助于更好地选择和确定辅助化疗候选患者的潜在风险因素。它最近才被引入老年肿瘤学领域,人们对其重要性缺乏认识。关于BC辅助化疗的现有数据有限,但表明对于精心挑选的患者可能有益,尽管短期和长期毒性风险很大。在此,我们讨论老年BC患者辅助化疗决策中的关键实际问题。